Anti-tumor activities of decursinol angelate and decursin fromAngelica gigas

Lee, Sang‐Hyun; Lee, Yeon Sil; Jung, Sang Hoon; Shin, Kuk Hyun; Kim, Bak-Kwang; Kang, Sam Sik

doi:10.1007/bf02976682

Cited by 136 publications

(114 citation statements)

References 7 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…The multiple pharmacological activities reported for A. gigas include antibacterial, antiplatelet aggregation, antioxidant, antinematodal, and also anticancer [12]. INM-176 has been reported as neuroprotective agent as it reduces the lipopolysaccharide-induced neuronal injury and also improves the scopolamine-induced cognitive dysfunction through inhibiting the various proinflammatory mediators as well as by inhibiting the AchE (anticholinesterase).The constituents such as decursin, decursinol angelate, chlorogenic acid, and ferulic acid have been reported to have antioxidant activity [10,11,19]. Therefore, it may be possible In the present study, global ischemia accompanied by reperfusion for 30 and 120 minutes, respectively, was given and it results into oxidative stress associated with increased in formation of various ROS which may be responsible for myocardial injury.…”

Section: Discussionmentioning

confidence: 99%

Cardioprotective Effect of Inm 176 on Ischemia Reperfusion Injury Using Rat Heart Model

Kumar

Khurana

Kaur

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Cardioprotective effect of INM-176 in ischemia reperfusion (I/R) injury in rat heart was evaluated by measuring the extent of release of the enzyme lactate dehydrogenase (LDH) and creatine phosphokinase (CK) and by measuring the myocardial infarction (MI) size.Methods: Five groups of animals were employed. Animals were sacrificed, and heart was mounted over the Langendorff's apparatus. Group I was employed as control group, Group II was the myocardial ischemic (MI) group, and Group III, IV, and V were pre-treated with different doses of INM-176 (150, 300, and 600 mg/kg). After this, global ischemia accompanied by reperfusion for 30 and 120 minutes was given, respectively. The effluent was collected from coronary vessel before the initiation of ischemia, immediately, after 5 and 30 minutes of reperfusion. The magnitude of myocardial injury was measured by LDH and CK release in coronary effluent. MI size was also evaluated macroscopically using triphenyl tetrazolium chloride staining. Results:In the present study, INM-176 was found to produce a dose-dependent cardioprotective effect against I/R injury, as observed by a decrease in the level of LDH, CK, and infarct size. Pre-treatment with a dose of 600 mg/kg was found to be more effective as compared to 150 and 300 mg/kg dose of INM-176. Conclusion:INM-176 pre-treatment at a dose of 600 mg/kg provides cardioprotection against I/R-induced myocardial injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardioprotective Effect of Inm 176 on Ischemia Reperfusion Injury Using Rat Heart Model

Kumar

Khurana

Kaur

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Many studies have been undertaken to elucidate the anticancer effects of decursin on apoptosis induction and inhibition of cell growth in several cancer cell lines (8,9). However, the molecular mechanism by which decursin inhibits cell proliferation, including cross-talk between the cell cycle and the signaling pathway, is not yet understood.…”

Section: Discussionmentioning

confidence: 99%

“…There are some reports about the pharmacological effects of this compound showing anti-bacterial and anti-leukemic activity, activation of protein kinase C, an and anti-angiogenic effect (3)(4)(5)(6)(7). Decursin reportedly inhibits growth and promotes apoptosis in several other cancer cells (8,9). However, there has been no report of the relationship between cell cycle regulation and the extracellular signal-regulated kinases (ERK) activation in impairing the growth of cancer cells.…”

Section: Introductionmentioning

confidence: 99%

Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation

Kim

Lee

Choi³

et al. 2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Decursin, a pyranocoumarin isolated from the KoreanAngelica gigas root, has demonstrated anti-cancer properties. In the present study, we found that decursin inhibited cell viability in cultured human urinary bladder cancer 235J cells and colon cancer HCT116 cells. The inhibited proliferation was due to apoptotic induction, because both cells treated with decursin dose-dependently showed a sub-G1 phase accumulation and an increased cytoplasmic DNA-histone complex. Cell death caused by decursin was also associated with the downregulation of anti-apoptotic factor Bcl-2 and the up-regulation of pro-apoptotic molecules cytochrome c, caspase 3 and Bax. Treatment of both types of cancer cells with decursin resulted in G1-phase cell cycle arrest, as revealed by FACS analyses. In addition, decursin increased protein levels of p21WAF1 with a decrease in cyclins and cyclin dependent kinases (CDKs). Furthermore, decursin induced the activation of extracellular signal-regulated kinases (ERK) in both cancer cell lines, with the notable exceptions of c-Jun N-terminal kinase (JNK) and p38 mitogen activated protein (MAP) kinase. Finally, pretreatment with ERK-specific inhibitor PD98059 reversed decursin-induced p21WAF1 expression and decursin-inhibited cell growth. Thus, these findings suggest that decursin has potential therapeutic efficacy for the treatment of bladder and colon cancer.

show abstract

“…Earlier investigations on the chemical constituents of A. gigas mainly dealt with the isolation of coumarins (Ryu et al, 1990;Jung et al, 1991;Pachaly et al, 1996;Lee et al, 2002). The literature survey revealed that several pharmacological works, anti-tumor, inhibition of hepatic microsomal drug metabolizing enzyme, and inhibition of acetylcholinesterase activities, have been carried out on A. gigas (Shin et al, 1996;Kang et al, 2001;Lee et al, 2003;Lee et al, 2009; Decursin was purifi ed from Angelica gigas Nakai, and its effects on the human Kv1.5 (hKv1.5) currents were recorded in mouse fi broblasts (Ltk − cells) by whole-cell patch-clamp technique. Decursin inhibited hKv1.5 current in a concentration-dependent manner, with an IC 50 value of 2.7 μM at +60 mV.…”

Section: Introductionmentioning

confidence: 99%

Decursin from Angelica gigas Nakai Blocks hKv1.5 Channel

Kwak¹,

Choi²,

Kim³

et al. 2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Kim et al., 2010). Our studies have focused on the development of antiarrhythmic drug, and we previously reported that papaverine (Choe et al., 2003), oxypeucedanin (Eun et al., 2005b), psoralen and their derivatives (Eun at al., 2005a;Eun et al., 2007) and torilin (Kwak et al., 2006) inhibited the hKv1.5 current. The present study was examined to investigate the effect of decursin from A. gigas on hKv1.5 channels using the whole-cell patch-clamp technique.

show abstract

Anti-tumor activities of decursinol angelate and decursin fromAngelica gigas

Cited by 136 publications

References 7 publications

Cardioprotective Effect of Inm 176 on Ischemia Reperfusion Injury Using Rat Heart Model

Cardioprotective Effect of Inm 176 on Ischemia Reperfusion Injury Using Rat Heart Model

Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation

Decursin from Angelica gigas Nakai Blocks hKv1.5 Channel

Contact Info

Product

Resources

About